baricitinib + probenecid

**Baricitinib + probenecid** is a combination of two small molecule drugs: baricitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor primarily used to treat moderately to severely active rheumatoid arthritis, severe alopecia areata, and COVID-19, and probenecid, a uricosuric agent known as a strong inhibitor of the organic anion transporter 3 (OAT3). When administered together, probenecid increases the plasma concentration of baricitinib by inhibiting its renal clearance through OAT3. This combination is not an approved fixed-dose product but may be encountered in the context of drug interaction studies, with guidelines recommending dosage reduction of baricitinib if used concomitantly with probenecid, due to increased baricitinib exposure. This combination is not recommended except in situations where co-administration is deemed necessary[1][2][3][4].